Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06736288
NCT06736288RecruitingPhase 4

Randomized, Double Blind, Placebo Controlled, Two-Arms, Multicenter, Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).

Laboratorio Farmaceutico SIT srl10 sites in 2 countries240 target enrollmentStarted: October 21, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor
Enrollment
240
Locations
10
Primary Endpoint
RLRTIs Episodes: Reduction in the number of infection episodes in the treatment period (12 months) in the Buccalin® group versus the Placebo group.
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The goal of this clinical trial is to assess if BUCCALIN® works In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIS). It will also evaluate the safety of BUCCALIN®.

The primary aim is to reduce the number of infection episodes in the treatment period (12 months) in the BUCCALIN® group versus the Placebo group.

Patients diagnosed with RLRTIS will be screened for enrolment. Patients will be requested to provide informed consent before the start of the study related assessments.

Eligible patients who meet the study inclusion and exclusion criteria will be randomized with a 1:1 ratio allocation to the 2 treatment groups.

Researchers will compare BUCCALIN® (gastro-resistant tablets) to a placebo (gastro-resistant tablets containing only excipients) to treat RLRTIS.

Patients who participate in the study will perform several study visits divided as reported below:

  • Run-in phase (12 months): patients will not receive any treatment. This phase is designed to increase adherence to the study and reduce loss to follow-up in the clinical trial. During this phase, patients should experience ≥ 2 episodes of RTIs to be eligible for the Treatment period.
  • Treatment period (12 months): patients will receive BUCCALIN® or Placebo treatment for 12 consecutive months (3 days per month, posology as per authorized SmPC).
  • Follow-up period (12 months): patients will not receive any treatment. This phase is designed to observe how patients respond to treatments.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients willing and able to provide voluntary informed consent and to follow protocol requirements.
  • •Male or females from 18 to 99 years old, (Adult, Older Adult).
  • •Patients with Recurrent LRTIs including tracheitis, tracheobronchitis, acute bronchitis and exacerbations of chronic lung disease (asthma and/or COPD and/or bronchiectasis), who present with both of the following:
  • •a) ≥2 episodes within 12 months prior to the run-in period based on patient reported medical history (to access the run-in period) b) ≥2 episodes during the run-in period documented by appropriate microbiological diagnostic test (to access the treatment period)
  • •not vaccinated or
  • •vaccinated against the most common pathogens for respiratory infectioan (within 12 months prior to the run-in period or during the run-in period, but not during the treatment period)*:
  • •- Anti-pertussis vaccination
  • •- Covid-19 vaccination
  • •- Respiratory Syncytial Virus vaccination
  • •- Influenza vaccination
  • •- Pneumococcal vaccination
  • •* Patients vaccinated with other types of vaccines that have no effect on the lower respiratory tract (e.g. hepatitis b vaccination, shingles/herpes zoster vaccination, papilloma virus vaccine), in addition to the ones listed above, may also be included.

Exclusion Criteria

  • •RUN-IN period
  • •Female patient: pregnant, lactating or planning pregnancy (Female of child-bearing potential will undergo urine pregnancy test).
  • •Female of potential child-bearing that does not use at least one effective contraceptive method for the entire study.
  • •Contraindication or known hypersensitivity to the active ingredients of bacterial lysates or any excipients listed in the ingredients.
  • •Pneumonia (based on the EMA Referral Procedure EMEA/H/A-31/1465).
  • •Known history of tuberculosis and/or cystic fibrosis.
  • •Known history of immunodeficiency diseases (e.g., HIV infection, AIDS, or any type of congenital or iatrogenic immune deficiency, including IgA deficiency).
  • •Severe heart failure (NYHA class III and IV).
  • •Haematologic diseases including severe anaemia (defined according to the National Cancer Institute as Hemoglobin < 8.0 g/dL).
  • •Renal failure (eGFR < 30 mL/min).
  • •History of known liver damages defined by the METAVIR classification (F1-F4)*.
  • •Malignancies with a remission period of < 5 years.
  • •Wheezing documented to be caused by gastroesophageal reflux**.
  • •Patient legally or mentally incapacitated unable to give informed consent for the participation in this study.
  • •Patient who is unable or unwilling to comply with the appointments or with all the requirements of the Protocol.
  • •History of autoimmune diseases and acute intestinal infections, as reported in Buccalin® SmPC.
  • •This criterion only applies to patients with known liver disease who can produce valid fibroscan and/or biopsy results and bring them for demonstration.
  • •The criterion can only be applied if the patient presents clinically reliable documentation that the wheezing is not due to a lung disease (i.e. gastroscopy).
  • •TREATMENT period
  • •Female patient: pregnant, lactating or planning pregnancy (Female of child-bearing potential will undergo urine pregnancy test).
  • •Female of potential child-bearing that does not use at least one effective contraceptive method for the entire study.
  • •Contraindication or known hypersensitivity to the active ingredients of bacterial lysates or any excipients listed in the ingredients.
  • •Pneumonia (based on the EMA Referral Procedure EMEA/H/A-31/1465).
  • •Known history of tuberculosis and/or cystic fibrosis.
  • •Known history of immunodeficiency diseases (e.g., HIV infection, AIDS, or any type of congenital or iatrogenic immune deficiency, including IgA deficiency).
  • •Severe heart failure (NYHA class III and IV).
  • •Haematologic diseases including severe anaemia (defined according to the National Cancer Institute Hemoglobin < 8.0 g/dL).
  • •Renal failure (eGFR < 30 mL/min).
  • •History of known liver damages defined by the METAVIR classification (F1-F4)*.
  • •Malignancies with a remission period of < 5 years.
  • •Injection or oral administration of steroids within 4 weeks prior to randomization**.
  • •Use of immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to randomization.
  • •Previous use within 6 months prior to randomization or ongoing use of bacterial lysates.
  • •Any major surgery within the last 3 months prior to randomization.
  • •Wheezing documented to be caused by gastroesophageal reflux***.
  • •Patient legally or mentally incapacitated unable to give informed consent for the participation in this study.
  • •Patient who is unable or unwilling to comply with the appointments or with all the requirements of the Protocol.
  • •History of autoimmune diseases and acute intestinal infections, as reported in Buccalin® SmPC.
  • •This criterion only applies to patients with known liver disease who can produce valid fibroscan and/or biopsy results and bring them for demonstration.
  • •In these instances, patients may undergo a washout period of 4 weeks to qualify for the treatment period.
  • •The criterion can only be applied if the patient presents clinically reliable documentation that the wheezing is not due to a lung disease (i.e. gastroscopy).

Arms & Interventions

BUCCALIN® gastro-resistant tablets

Active Comparator

mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae

Intervention: BUCCALIN® (Drug)

Placebo

Placebo Comparator

gastro-resistant tablets containing only excipients

Intervention: Placebo (Other)

Outcomes

Primary Outcomes

RLRTIs Episodes: Reduction in the number of infection episodes in the treatment period (12 months) in the Buccalin® group versus the Placebo group.

Time Frame: From the enrollment to the end of the treatment at 24 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Laboratorio Farmaceutico SIT srl
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (10)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy AdultsInfrequent Bowel Movements
NCT06686420Morinaga Milk Industry Co., LTD80
Completed
Phase 2
Prevention Of Recurrence Of Atrial FibrillationFibrillation, Atrial
NCT00041496GlaxoSmithKline520
Active, not recruiting
Phase 2
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
NCT06736990Calluna Pharma AS150
Completed
Phase 3
Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent PatientsAlcohol Dependence
NCT01738282Ethypharm316
Completed
Phase 3
Coenzyme Q10 Phase III Trial in Gulf War IllnessGulf War IllnessChronic FatigueUbiquinolCoenzyme Q10
NCT02865460VA Office of Research and Development100
Post Authorization Efficacy and Safety... | Clinical Trial